These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23054648)

  • 81. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 82. FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.
    L'Abbate A; Lo Cunsolo C; Macrì E; Iuzzolino P; Mecucci C; Doglioni C; Coco M; Muscarella LA; Salati S; Tagliafico E; Minoia C; De Tullio G; Guarini A; Testoni N; Agostinelli C; Storlazzi CT
    BMC Cancer; 2014 Jun; 14():396. PubMed ID: 24893616
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1.
    van de Loosdrecht AA; Kok K; de Vries B; van der Veen AY; van den Berg E; Esselink MT; Marynen P; Vellenga E; van Imhoff GW
    Leukemia; 2000 Oct; 14(10):1857-8. PubMed ID: 11021761
    [No Abstract]   [Full Text] [Related]  

  • 84. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
    Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
    PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
    [TBL] [Abstract][Full Text] [Related]  

  • 87. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
    Bard-Chapeau EA; Szumska D; Jacob B; Chua BQ; Chatterjee GC; Zhang Y; Ward JM; Urun F; Kinameri E; Vincent SD; Ahmed S; Bhattacharya S; Osato M; Perkins AS; Moore AW; Jenkins NA; Copeland NG
    PLoS One; 2014; 9(2):e89397. PubMed ID: 24586749
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Acute myelogenous leukemia with monosomy 7, inv(3) (q21q26), involving activated EVI 1 gene occurring after a complete remission of lymphoblastic lymphoma: a case report.
    Igarashi T; Shimizu S; Morishita K; Ohtsu T; Itoh K; Minami H; Fujii H; Sasaki Y; Mukai K
    Jpn J Clin Oncol; 1998 Nov; 28(11):688-95. PubMed ID: 9861236
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The 5q- syndrome: biology and treatment.
    Padron E; Komrokji R; List AF
    Curr Treat Options Oncol; 2011 Dec; 12(4):354-68. PubMed ID: 21964863
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.
    Dickstein J; Senyuk V; Premanand K; Laricchia-Robbio L; Xu P; Cattaneo F; Fazzina R; Nucifora G
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9783-8. PubMed ID: 20448201
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
    Archimbaud E; Charrin C; Magaud JP; Campos L; Thomas X; Fière D; Rimokh R
    Leukemia; 1998 Jan; 12(1):25-33. PubMed ID: 9436917
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
    Peeters P; Wlodarska I; Baens M; Criel A; Selleslag D; Hagemeijer A; Van den Berghe H; Marynen P
    Cancer Res; 1997 Feb; 57(4):564-9. PubMed ID: 9044825
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The 5q-anomaly.
    Van den Berghe H; Vermaelen K; Mecucci C; Barbieri D; Tricot G
    Cancer Genet Cytogenet; 1985 Jul; 17(3):189-255. PubMed ID: 3891074
    [TBL] [Abstract][Full Text] [Related]  

  • 99. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
    Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
    Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
    Vlachos A; Farrar JE; Atsidaftos E; Muir E; Narla A; Markello TC; Singh SA; Landowski M; Gazda HT; Blanc L; Liu JM; Ellis SR; Arceci RJ; Ebert BL; Bodine DM; Lipton JM
    Blood; 2013 Oct; 122(14):2487-90. PubMed ID: 23943650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.